Study the target
Explore the biology of EGFR and the context in which its signaling contributes to cancer.
ONCOLOGY / TARGETED PROTEIN DEGRADATIONA different
A different
approach
to EGFR.
Investigating protein degradation as a path toward new cancer therapies.
Dvant Pharma is focused on developing novel EGFR degraders for solid tumors. Our work is rooted in oncology research and the pursuit of a deeper understanding of the target.
OncologyEGFR degradationResearch-driven development
Changing the question.
From activity to abundance.
EGFR helps transmit signals involved in cell growth and survival. A degradation strategy asks whether reducing the protein itself can create a useful therapeutic approach.
Evaluate degradation
Investigate approaches intended to reduce the target protein, alongside careful assessment of selectivity and biological effects.
Build the evidence
A therapeutic hypothesis requires experimental support, safety evaluation, and further development before clinical use.
PUBLICLY REPORTED PROGRAM
DPI-503
Listed for cancer in the University of Michigan drug pipeline.
View program contextREPORTED DEVELOPMENT STAGEPreclinical
University of Michigan report · December 2025
A dated public record. It does not establish a current clinical stage, approval, or patient benefit.
Focused science.
Thoughtful next steps.
The company’s direction brings together drug development and scientific collaboration. This website separates public records from future research and partnership plans.
A clear mechanism question
Learn why EGFR degradation is a focus for research, without assuming clinical benefit.
Data that can be reviewed
Explore a proposed approach to organizing and analyzing research data in the cloud.
A constructive starting point
Discuss scientific fit, development needs, and potential collaboration scope.
SCIENTIFIC & STRATEGIC PARTNERSHIPSMove the science
Connect with Dvant Move the science
forward. Together.
Start a nonconfidential conversation with Dvant Pharma.